Analyst consensus

As at 13 March 2023

FY23

 

Low

High

Average (Mean)

Revenue (£m)

1,267.0

1,317.0

1,287.6

EBITDA (£m)

223.7

239.1

229.3

EBIT (£m)

121.0

134.0

126.6

PBT (£m)

27.0

39.2

32.2

Net income (£m)

16.6

27.8

22.3

Adjusted EPS (p)

4.5

6.9

5.6

Net bank debt (£m)

(222.1)

(220.0)

(221.1)

Net debt (including lease liabilities) (£m)

(1,124.0)

(1,090.6)

(1,103.5)

FY24

 

Low

High

Average (Mean)

Revenue (£m)

1,322.2

1,426.0

1,362.2

EBITDA (£m)

249.2

264.7

255.2

EBIT (£m)

137.0

158.3

147.5

PBT (£m)

43.0

63.1

52.7

Net income (£m)

18.5

47.3

36.2

Adjusted EPS (p)

7.3

11.8

9.6

Net bank debt (£m)

(190.9)

(176.0)

(183.5)

Net debt (including lease liabilities) (£m)

(1,117.0)

(1,061.4)

(1,081.1)

 

The figures shown above are on an adjusted, post IFRS 16 basis. They include estimates from five analysts at the following institutions who have updated their estimates in line with Company guidance following Spire Healthcare’s FY22 results: Barclays, Berenberg, JPM, Numis and RBC.